Neuromed's long-acting opioid Exalgo heads for US panel review
This article was originally published in Scrip
The US FDA's anaesthetic and life support drugs advisory panel will review Neuromed Pharmaceuticals' extended-release opioid Exalgo (hydromorphone HCl) on September 23rd. The proposed indication is treatment of moderate to severe pain in opioid-tolerant patients.
You may also be interested in...
Chronicle of the development and review of Sarepta’s golodirsen for treatment of Duchenne muscular dystrophy patients with a genetic mutation amenable to exon 53 skipping.
ODE I director Ellis Unger chafed at the notion of approving the Duchenne muscular dystrophy drug golodirsen on the same unvalidated surrogate marker, this time in the face of infection and renal toxicity concerns; OND’s Peter Stein granted Sarepta’s appeal while also calling attention to the company’s failure to timely conduct the eteplirsen confirmatory trial.
Advisory committee votes 24-2 against approval of Intellipharmaceutics’ Aximris XR due to concerns the extended-release oxycodone formulation may be more susceptible to intranasal abuse than existing products; Esteve fares better with its tramadol/celecoxib combination, securing a tie vote on approval for acute pain.